HomeInsightsStock Comparison

Natco Pharma Ltd vs Wockhardt Ltd Stock Comparison

Natco Pharma Ltd vs Wockhardt Ltd Stock Comparison

Last Updated on: Jun 01, 2025

Key Highlights

  • The Latest Trading Price of Natco Pharma Ltd is ₹ 883.45 as of 30 May 15:30.
  • The P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.6 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
  • The Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 1912 crore on March 2020 to ₹ 8951 crore on March 2024 . This represents a CAGR of 36.16% over 5 years.
  • The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71% The revenue of Wockhardt Ltd for the Mar '25 is ₹ 758 crore as compare to the Dec '24 revenue of ₹ 729 crore. This represent the growth of 3.98%.
  • The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63% The ebitda of Wockhardt Ltd for the Mar '25 is ₹ 79 crore as compare to the Dec '24 ebitda of ₹ 136 crore. This represent the decline of -41.91%.
  • The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% The net profit of Wockhardt Ltd changed from ₹ -136 crore to ₹ -45 crore over 8 quarters. This represents a CAGR of -42.48% .
  • The Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Natco Pharma Ltd

  • Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited.
  • It became a deemed public company with effect from 1 July 1992.
  • The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993.
  • The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.

About Wockhardt Ltd

  • Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
  • The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
  • It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
  • It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
  • Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

Natco Pharma Ltd News Hub

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

News

Natco Pharma Ltd up for fifth session

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 8...

Read more

07 Mar 2025 13:00

News

Natco Pharma Ltd soars 1.69%

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837...

Read more

25 Feb 2025 13:05

News

Natco Pharma slips as Q3 PAT slides 38% YoY to Rs 132 cr

Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 cror...

Read more

13 Feb 2025 11:11

Wockhardt Ltd News Hub

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025. Pow...

Read more

24 May 2025 18:26

News

Wockhardt announces incorporation of step-down subsidiary in Ireland

Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiar...

Read more

08 Apr 2025 19:55

News

Wockhardt surges after breakthrough US cancer treatment with Zaynich

The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a ...

Read more

01 Apr 2025 11:32

News

Wockhardt announces board meeting date

Wockhardt will hold a meeting of the Board of Directors of the Company on 7 February 2025....

Read more

03 Feb 2025 16:52

News

Wockhardt spurts after Indian drug regulator approves Pneumonia antibiotic

Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP, including those cau...

Read more

03 Jan 2025 11:22

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024...

Read more

08 Nov 2024 16:42

SWOT Analysis Of Wockhardt Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Wockhardt Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Natco Pharma Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Natco Pharma Ltd or Wockhardt Ltd?

Market cap of Natco Pharma Ltd is 15,823 Cr while Market cap of Wockhardt Ltd is 23,796 Cr

What are the key factors driving the stock performance of Natco Pharma Ltd and Wockhardt Ltd?

The stock performance of Natco Pharma Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Natco Pharma Ltd and Wockhardt Ltd?

As of June 1, 2025, the Natco Pharma Ltd stock price is INR ₹883.45. On the other hand, Wockhardt Ltd stock price is INR ₹1464.5.

How do dividend payouts of Natco Pharma Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Natco Pharma Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions